ArticleAMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science2013
Extending the "web of drug identity" with knowledge extracted from United States product labels.
Article in AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The heterogeneous pharmacological medical biochemical network PharMeBINet.Scientific data · 2022Article
- Exploring Novel Computable Knowledge in Structured Drug Product Labels.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2020Article
- Article
- Ontology-based collection, representation and analysis of drug-associated neuropathy adverse events.Journal of biomedical semantics · 2016Article
- Toward a complete dataset of drug-drug interaction information from publicly available sources.Journal of biomedical informatics · 2015Article
- Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug repurposing.BioData mining · 2015Article
- Disambiguation of PharmGKB drug-disease relations with NDF-RT and SPL.Journal of biomedical informatics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Structured Product Labels (SPLs) contain information about drugs that can be valuable to clinical and translational research, especially if it can be linked to other sources that provide data about drug targets, chemical properties, interactions, and biological pathways. Unfortunately, SPLs currently provide coarsely-structured drug information and lack the detailed annotation that is required to support computational use cases. To help address this issue we created LinkedSPLs, a Linked Data resource that extends the "web of drug identity" using information extracted from SPLs. In this paper we describe the mapping that LinkedSPLs provides between SPL active ingredients and DrugBank chemical entities. These mappings were created using three approaches: InChI chemical structure descriptors comparison, exact string matching based on the chemical name, and automatic (unsupervised) linkage identification. Comparison of the approaches found that, while these three approaches are complementary, the automatic approach performs well in terms of precision and recall.
Identifiers
24303301PMC3814463What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.